Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Myelofibrosis+3

Recruiting

Registered drugNo placebo

Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Myelofibrosis+1

Recruiting

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Myelofibrosis

Recruiting

InvestigationalNo placebo

A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pacritinib

Contact Research Centre

Myelofibrosis

Recruiting

Registered drugNo placebo

Study on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Fedratinib

Contact Research Centre

Myelofibrosis

Recruiting

InvestigationalNo placebo

Study of TP-3654 and Momelotinib for Patients with Intermediate or High-risk Myelofibrosis

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate

Contact Research Centre

Myelofibrosis+1

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate

Contact Research Centre

Myelofibrosis

Recruiting

Registered drug

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Navtemadlin

Contact Research Centre

Myelofibrosis+1

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Navtemadlin

Contact Research Centre

Myelofibrosis+4

Recruiting

Registered drugNo placebo

Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Luspatercept

Contact Research Centre

Myelofibrosis+2

Recruiting

InvestigationalNo placebo

Study on the Safety of Bomedemstat for Patients with Myeloproliferative Neoplasms Who Participated in a Previous Bomedemstat Study

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bomedemstat

Contact Research Centre

Myelofibrosis

Recruiting

Registered drugNo placebo

Study for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Myelofibrosis+1

Recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Aprepitant

Contact Research Centre

Find therapies in clinical trials near you

31 trials match your criteria

Myelofibrosis+3

Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

Myelofibrosis+1

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Myelofibrosis

A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

Myelofibrosis

Study on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors

Myelofibrosis

Study of TP-3654 and Momelotinib for Patients with Intermediate or High-risk Myelofibrosis

Myelofibrosis+1

Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

Myelofibrosis

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Myelofibrosis+1

Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis+4

Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

Myelofibrosis+2

Study on the Safety of Bomedemstat for Patients with Myeloproliferative Neoplasms Who Participated in a Previous Bomedemstat Study

Myelofibrosis

Study for Myelofibrosis Patients Using Ruxolitinib or Ruxolitinib with Other Cancer Treatments

Myelofibrosis+1

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.